12:00 AM
 | 
Aug 31, 2009
 |  BC Week In Review  |  Company News  |  Deals

Dyax, AstraZeneca deal

Dyax will receive an undisclosed milestone payment from AstraZeneca's MedImmune Inc. subsidiary under a 2003 deal granting MedImmune a non-exclusive license to Dyax's...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >